The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

The FDA has granted rare paediatric disease and orphan drug designations for IN013, Innorna's mRNA therapeutic for Wilson's ...

Amgen has announced a significant expansion of the Ohio manufacturing facility in the US, with an investment of $900m.

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.